Summary of Globus Medical (GMED) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $789.6 million, up 6% year-over-year; 9% growth excluding Nevro.

Earnings: Fully diluted non-GAAP EPS of $1.34, a 56% increase from the prior year.

Adjusted EBITDA: 35.4%, up 740 basis points year-over-year.

Musculoskeletal Sales: $763.5 million, an 8% increase year-over-year.

International Spine Growth: 14% year-over-year.

Cash Position: $840.5 million, up from $629.1 million at year-end 2025.

Share Repurchases: $136 million spent to repurchase 1.6 million shares.

2Strategic Updates and Business Highlights

Product Development: Launched 3 new products in Q2, including innovations in trauma and spine.

Market Share: U.S. Spine grew 7%, with strong procedural volumes and competitive recruiting contributing to growth.

Acquisitions: Integration of Nevro is ongoing, with expectations for trial volumes to recover by Q4 2026.

Focus on Innovation: Over 60 projects in development, emphasizing organic growth and product differentiation.

Enabling Technologies: Shift towards flexible capital acquisition models is underway, with early signs of success.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reaffirmed at $3.18 billion to $3.22 billion, implying growth of 8.2% to 9.6% over 2025.

EPS Guidance: Increased to $4.95 to $5.05, reflecting improved margin expectations.

Long-term Goals: Targeting mid-70s adjusted gross profit margins and mid-30s EBITDA margins by 2027.

4Bad News, Challenges, or Points of Concern

Decline in Nevro Sales: Sales flat compared to Q1, with a 14.3% decline year-over-year, indicating integration challenges.

Enabling Technologies Revenue: Down 26%, attributed to the transition in capital acquisition strategy.

U.S. Spine Growth Rate: Slowed to 7% from previous quarters' higher growth rates, with tougher comps expected in the second half of the year.

Market Conditions: Potential headwinds in Europe due to transient issues like strikes and heat waves, although overall international growth remains strong.

5Notable Q&A Insights

International Growth: Management remains optimistic about sustained international growth despite some regional challenges.

U.S. Spine Outlook: Confidence in the U.S. Spine business remains, but tougher year-over-year comparisons may impact growth rates.

Nevro Integration: Management is cautious but optimistic about returning Nevro to historical sales levels, with a focus on trial volume recovery.

R&D Investment: Plans to ramp up R&D spending in the second half of 2026, focusing on core areas and software capabilities.

Sales Force Expansion: Strong hiring in the sales team is expected to drive future growth, particularly in the Nevro division. Overall, Globus Medical reported a strong Q2 2026, with significant growth in key areas despite some challenges in specific segments like Nevro and Enabling Technologies. The company is focused on innovation and strategic growth, positioning itself well for the remainder of the year and beyond.